Evaxion Biotech Past Earnings Performance
Past criteria checks 0/6
Evaxion Biotech's earnings have been declining at an average annual rate of -21.4%, while the Biotechs industry saw earnings growing at 14.5% annually.
Key information
-21.4%
Earnings growth rate
-8.4%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | n/a |
Return on equity | n/a |
Net Margin | n/a |
Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
No updates
Recent updates
Evaxion Biotech names Per Norlén as CEO
Oct 05Evaxion stock rises 11% as enrollment begins in trial of immunotherapy EVX-01 for skin cancer
Sep 21Evaxion Biotech ADS GAAP EPS of -$0.20 beats by $0.10
Aug 10Evaxion Biotech announces new CEO as Lars Wegner resigns
Aug 02Is Evaxion Biotech (NASDAQ:EVAX) In A Good Position To Invest In Growth?
Oct 27We're Hopeful That Evaxion Biotech (NASDAQ:EVAX) Will Use Its Cash Wisely
Jun 29Evaxion Biotech posts preclinical proof of concept data for AI-powered vaccine platform
Jun 03Revenue & Expenses BreakdownBeta
How Evaxion Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 23 | 0 | -24 | 11 | 14 |
30 Jun 23 | 0 | -25 | 10 | 15 |
31 Mar 23 | 0 | -24 | 9 | 16 |
31 Dec 22 | 0 | -23 | 8 | 17 |
30 Sep 22 | 0 | -25 | 7 | 19 |
30 Jun 22 | 0 | -24 | 7 | 19 |
31 Mar 22 | 0 | -26 | 7 | 20 |
31 Dec 21 | 0 | -25 | 6 | 20 |
30 Sep 21 | 0 | -20 | 6 | 16 |
30 Jun 21 | 0 | -19 | 7 | 15 |
31 Mar 21 | 0 | -16 | 6 | 12 |
31 Dec 20 | 0 | -15 | 6 | 11 |
30 Sep 20 | 0 | -14 | 5 | 11 |
31 Dec 19 | 0 | -11 | 3 | 8 |
Quality Earnings: EVAX is currently unprofitable.
Growing Profit Margin: EVAX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: EVAX is unprofitable, and losses have increased over the past 5 years at a rate of 21.4% per year.
Accelerating Growth: Unable to compare EVAX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EVAX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: EVAX's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.